Nicholas Don-Doncow

Research Scientist at BioInvent International

Nicholas Don-Doncow has extensive work experience in various research positions and temporary jobs. Nicholas is currently employed as a Research Scientist at BioInvent International AB since June 2021. Prior to this, they worked as a Post Doctoral Researcher at Lund University from October 2017 to May 2021, where they focused on investigating the S1P pathway and its influence on hypertension. Nicholas also trained students in carrying out experiments during this role.

Before their postdoctoral research, Nicholas worked at Lund University in different roles, including Research Assistant, PhD student, Research Stipend, and Masters Thesis. Nicholas was involved in research projects related to their studies in the field.

In addition to their research experience, Nicholas had temporary jobs during summers in the San Francisco Bay Area through Adecco Group. These roles varied in sales and service industries, working for companies such as Verizon, Bank of America, Wells Fargo bank, and the San Mateo realtors association.

Early in their career, Nicholas worked at UC San Diego as a Lab Assistant, assisting a PhD student in designing a next-generation sequencer. Nicholas also worked as a Lab Project staff at Lund University and served as Nature Staff at Camp Royaneh.

Overall, Nicholas Don-Doncow's work experience demonstrates expertise in research, project management, training, and a diverse range of skills gained from various roles.

Nicholas Don-Doncow pursued a Bachelor of Science degree in Molecular Biology at UC San Diego from 2006 to 2010. Following this, they continued their education at Lund University, where they obtained a Master of Science degree in Molecular Biology between 2010 and 2012. Nicholas then proceeded to complete their Doctor of Philosophy (PhD) in Medical Clinical Sciences/Graduate Medical Studies from Lund University from 2013 to 2017.

Location

Lund, Sweden

Links


Org chart

No direct reports

Teams


Offices


BioInvent International

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.


Industries

Headquarters

Lund, Sweden

Employees

51-200

Links